Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,426 Million (Mid Cap)
65.00
NA
0.00%
0.05
5.82%
3.78
Revenue and Profits:
Net Sales:
433 Million
(Quarterly Results - Jun 2025)
Net Profit:
57 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
16.67%
0%
16.67%
6 Months
51.08%
0%
51.08%
1 Year
66.67%
0%
66.67%
2 Years
68.67%
0%
68.67%
3 Years
72.13%
0%
72.13%
4 Years
70.04%
0%
70.04%
5 Years
112.12%
0%
112.12%
Zhejiang Hengtong Holding Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.96%
EBIT Growth (5y)
11.87%
EBIT to Interest (avg)
-50.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.25
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.13%
ROE (avg)
7.93%
Valuation key factors
Factor
Value
P/E Ratio
65
Industry P/E
Price to Book Value
3.78
EV to EBIT
-224.83
EV to EBITDA
159.73
EV to Capital Employed
3.64
EV to Sales
8.62
PEG Ratio
4.36
Dividend Yield
NA
ROCE (Latest)
-1.62%
ROE (Latest)
5.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
433.10
380.00
13.97%
Operating Profit (PBDIT) excl Other Income
33.10
28.20
17.38%
Interest
6.00
7.80
-23.08%
Exceptional Items
0.90
-1.00
190.00%
Consolidate Net Profit
56.80
70.10
-18.97%
Operating Profit Margin (Excl OI)
10.20%
-1.20%
1.14%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 13.97% vs -10.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -18.97% vs 3,589.47% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,323.10
639.60
106.86%
Operating Profit (PBDIT) excl Other Income
88.60
59.30
49.41%
Interest
23.20
6.70
246.27%
Exceptional Items
-23.90
-39.10
38.87%
Consolidate Net Profit
165.60
153.20
8.09%
Operating Profit Margin (Excl OI)
-13.10%
6.50%
-1.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 106.86% vs 7.24% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 8.09% vs -68.04% in Dec 2023
About Zhejiang Hengtong Holding Co., Ltd. 
Zhejiang Hengtong Holding Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






